戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 o are allergic but not from controls who are nonsensitized.
2 osomes from sensitized mothers compared with nonsensitized.
3    Seventy-two children were nonallergic and nonsensitized.
4 patients were sensitized to egg (69%) and 60 nonsensitized (31%).
5 ification of patients with CF into 3 groups: nonsensitized, A fumigatus-sensitized, and ABPA.
6                                              Nonsensitized and A. fumigatus-sensitized CBA/J mice rec
7 hat the response to acute methamphetamine in nonsensitized and saline-treated animals may be function
8 responses to prefrontal cortex activation in nonsensitized and saline-treated animals, but not in sen
9 g) abolished accumbens up and down states in nonsensitized and saline-treated animals, suggesting a d
10 effect of triplet matching was seen for both nonsensitized and sensitized patients and also for white
11 e behavioral distinction between sensitized, nonsensitized, and control rats in behavioral responsive
12 r activity than did the saline-pretreated or nonsensitized animals after AMPA injection into either s
13                    In sensitized, but not in nonsensitized animals, virus-induced hyperresponsiveness
14 nsiveness to methacholine when compared with nonsensitized animals.
15 reactivity in sensitized animals, but not in nonsensitized animals.
16 rway eosinophilia and AHR when compared with nonsensitized animals.
17  effect on cocaine-induced motor activity in nonsensitized animals.
18 timulated glucose responses in comparison to nonsensitized animals.
19 ed for the ability to induce ACAID in naive (nonsensitized) as well as T- and B-cell-deficient recipi
20 e lowest rate of allograft survival, whereas nonsensitized Asians had the highest survival.
21 tions contribute to normal gastrulation in a nonsensitized background.
22       Patients were considered sensitized or nonsensitized based on the frequencies of HLA-specific B
23  the apoptotic process compared with that in nonsensitized cells.
24 greater risk of developing viral wheeze than nonsensitized children (hazard ratio [HR], 1.9; 95% conf
25 h allergic asthma than those from in healthy nonsensitized children and that IL-13 treatment reduced
26 a limited number of allergens suggested that nonsensitized children produce IgG responses mainly to f
27 ean levels of IgG to allergenic molecules in nonsensitized children were lower at age 2 years than in
28 tly higher allergen-specific IgG levels than nonsensitized children.
29 a more proinflammatory (ie, M1) phenotype in nonsensitized children.
30 -sensitized children with asthma and healthy nonsensitized children.
31 n response to purified allergens compared to nonsensitized children.
32                                Compared with nonsensitized class, children in the class with sensitiv
33 actions take place under both sensitized and nonsensitized conditions, and they are highly stereosele
34 irradiation, with comparison to samples from nonsensitized control cultures.
35 vely expressed in lung tissue collected from nonsensitized control mice but increased levels were fou
36 ith (n = 55) or without (n = 17) asthma, and nonsensitized controls (n = 20).
37  and egg-sensitized 14-month-old infants and nonsensitized controls enrolled in HealthNuts, a populat
38 ntly greater in BCG responders compared with nonsensitized controls, indicating that BCG vaccination
39 nuated in EtOH-sensitized mice compared with nonsensitized counterparts.
40                                              Nonsensitized DO11.10 mice but not wild-type mice respon
41                                 In contrast, nonsensitized effector CD8 T cells responded robustly to
42  eotaxin-injected, 8.6 +/- 1.0 x 10(5)) than nonsensitized, eotaxin-injected mice (2.5 +/- 0.4 x 10(5
43                       (c) Low-risk patients (nonsensitized first transplantation) should be screened
44 wed hyperacute or acute humoral rejection in nonsensitized GalT KO mice with low levels of anti-alpha
45 in independent groups of EtOH-sensitized and nonsensitized genetically heterogeneous female mice afte
46 ar survival was 67% (95% CI, 0.5-0.8) in the nonsensitized group and 64% (95% CI, 0.3-0.9) in the sen
47 ere were six renal allograft failures in the nonsensitized group but none in the sensitized group.
48  the first injection of daily cocaine, and a nonsensitized group showing < 20% elevation.
49 ansplantation were similar: 1.5 mg/dL in the nonsensitized group versus 1.36 mg/dL in the sensitized
50 anti-Ova IgE levels that were similar to the nonsensitized group.
51 was no difference between the sensitized and nonsensitized groups (P>0.4 for all) in usage of blood p
52 similar levels of CTA in EtOH-sensitized and nonsensitized groups.
53 duced hyperreactivity and M2R dysfunction in nonsensitized guinea pigs.
54 ompared to TB disease and Mtb-sensitized and nonsensitized healthy cohorts.
55 nguished sarcoidosis from Mtb-sensitized and nonsensitized healthy controls combined (AUC = 0.91 and
56 ients with TB disease and Mtb-sensitized and nonsensitized healthy controls using flow cytometry and
57                                    Among 267 nonsensitized heart transplant recipients, switching fro
58 une responses in sensitized individuals, but nonsensitized individuals also are exposed to pollen.
59 a are quickly eliminated from the airways of nonsensitized individuals but persist in individuals wit
60 ent exacerbation of asthma, possibly even in nonsensitized individuals.
61                                   Of the 383 nonsensitized infants (56.7% male), 184 were randomized
62  IL-12p70 and lower IL-10 levels compared to nonsensitized infants.
63 tern of exposures, immunity, and outcomes to nonsensitized infants.
64  Antigen Flow Bead assays, 346 pretransplant nonsensitized kidney recipients were screened at 2 and 5
65 dneys at 8 years was significantly better in nonsensitized (&lt;20% panel reactive antibodies; 68% vs. 5
66                        Fifty-five previously nonsensitized LVAD recipients of a TCI device implanted
67 ear) tolerance to islet allografts in 5 of 5 nonsensitized, MHC class I-disparate, and one MHC class
68 s prior to implantation into ABO-compatible, nonsensitized, MHC-mismatched recipients.
69  higher in lungs of sensitized compared with nonsensitized mice after secondary infection, indicating
70 ved by 1 h after challenge of sensitized and nonsensitized mice and was dependent on TNF-alpha.
71 e levels observed in skin challenge sites of nonsensitized mice but rose to a second peak 12 h after
72 tent airway alterations were not observed in nonsensitized mice challenged with A. fumigatus conidia
73 ministration of anti-MCP-1/CCL2 antiserum to nonsensitized mice for14 days after the conidia challeng
74 ia, and peribronchial fibrosis compared with nonsensitized mice that received conidia and normal seru
75 ly elevated at days 3 and 7 after conidia in nonsensitized mice.
76  are smaller and less fibrotic than those in nonsensitized mice.
77 hilia and significant AHR when compared with nonsensitized mice.
78 challenged through the airways compared with nonsensitized mice.
79  in the lungs of sensitized as compared with nonsensitized mice.
80 ot observed in A-Tg grafts transplanted into nonsensitized mice.
81  in skin challenge sites of Ag-sensitized vs nonsensitized mice.
82 the OVA-sensitized and ragweed-challenged or nonsensitized mice.
83                                  Compared to nonsensitized monkeys, there was a fourfold reduction in
84  wheeze were significant in children born to nonsensitized mothers (any IgE <0.35 kU/L) but not in th
85            Pre-PHTx sensitization status was nonsensitized (n = 163, 44%), sensitized/no DSA (n = 115
86                              In the lungs of nonsensitized naive mice, IL-33-responsive cells were id
87                                              Nonsensitized (naive) and sensitized allograft recipient
88           The study includes 189 consecutive nonsensitized, non-HLA-identical patients who received a
89                 PA (n = 56), PS (n = 42) and nonsensitized nonallergic (NA, n = 10) patients were stu
90 ectable P-sIgG4 levels and POIT but not from nonsensitized nonallergic children.
91 108 patients with PA, 77 PS patients, and 43 nonsensitized nonallergic subjects) were studied.
92 n allergic (n = 79), sensitized (n = 40) and nonsensitized, nonallergic (n = 37) infants by multiplex
93 peripheral blood mononuclear cells (PBMC) of nonsensitized, 'not-yet' sensitized or sensitized childr
94 ling frame, participants were categorized as nonsensitized (NS), sensitizedtolerant (ST), or food all
95                                     Notably, nonsensitized obese mice already exhibited increased lun
96 e in the core of sensitized rats, but not of nonsensitized or control rats.
97 s persulfate and silver nitrate solution the nonsensitized particles evolve oxygen with initial rates
98 %-5.5%) among sensitized patients than among nonsensitized patients (1.6%-3.2%, P<0.001).
99    Pooled normal human AB sera and sera from nonsensitized patients (n=3) served as negative control.
100 d reduced cumulative rejections to levels in nonsensitized patients (P=0.003).
101                                   Records of nonsensitized patients (panel reactive antibodies [PRA]
102 FD of a zero-antigen mismatch was 0.046% for nonsensitized patients and 0.009% for highly sensitized
103             However, the survival benefit to nonsensitized patients is real and long lasting and will
104 (15-30 mg, 1 dose, subcutaneous), whereas 35 nonsensitized patients received anti-IL-2R.
105 ctional outcomes in HS pediatric patients as nonsensitized patients receiving anti-IL-2R induction.
106                      We randomly assigned 55 nonsensitized patients undergoing a first cardiac transp
107 s (95% confidence interval [CI], 47-135) for nonsensitized patients versus 151 months (95% CI, 4 to i
108 ensitized recipients or de novo responses in nonsensitized patients who are nonadherent.
109 red with those in A fumigatus-sensitized and nonsensitized patients with CF without ABPA.
110 AT discriminates A fumigatus-sensitized from nonsensitized patients with CF.
111 mass index in A fumigatus-sensitized but not nonsensitized patients with CF.
112 es greater than 85% and 50 randomly selected nonsensitized patients with PRA values less than 3%.
113  IgG isolated from normal AB serum and three nonsensitized patients, which was depleted of XNA (HLA-I
114 identify more suitably mismatched donors for nonsensitized patients.
115 herapy and subsequently approximated that in nonsensitized patients.
116  and higher chances for transplantation than nonsensitized patients.
117 y Luminex) have worse outcomes compared with nonsensitized patients.
118  0.4 (95% CI, 0.1-2.2) for sensitized versus nonsensitized patients.
119 ssful re-administration may have occurred in nonsensitized patients.
120 nsitized patients and from 5.4% to 19.6% for nonsensitized patients.
121 uced waiting time and mortality to levels in nonsensitized patients.
122          All kidneys were placed in primary, nonsensitized (peak PRA = 7.9+/-5.6%) adult (41.6+/-16 y
123 ms triplet lifetime for the more crystalline nonsensitized polymer C(2)C(6), 2-3 orders of magnitude
124 ulticenter, double-blinded clinical trial in nonsensitized primary heart transplant (HTX) recipients.
125 immunosuppression with RATG, FK, and MMF for nonsensitized primary kidney or kidney/pancreas transpla
126 Trial was a randomized, prospective study of nonsensitized primary recipients of living donor kidney
127                                              Nonsensitized primary renal allograft patients (n = 157)
128 nd AMR (32 and 38%) at 3 years compared with nonsensitized recipients (28 and 20%) (P=0.23 and 0.0001
129 loantibody were equivalent in sensitized and nonsensitized recipients 6 weeks after transplantation.
130 f de novo alloantibodies in immunosuppressed nonsensitized recipients and absence of donor HLA-specif
131                                        Seven nonsensitized recipients of living-donor kidneys were tr
132 -219)-reactive autoantibodies are induced in nonsensitized recipients of major histocompatibility com
133  to estimated half-lives of 10.3 years among nonsensitized recipients versus 7.8 years among sensitiz
134 trated to confer donor-specific tolerance in nonsensitized recipients, but has not been evaluated in
135 g is to control alloreactive host T cells in nonsensitized recipients, strikingly, none of the strate
136 t higher risk for Ab-mediated rejection than nonsensitized recipients, yet little is known about the
137 nsfer of anti-A antibody and complement into nonsensitized recipients.
138 after transplantation in both sensitized and nonsensitized recipients.
139 the waiting list with outcomes comparable to nonsensitized recipients.
140 asuring serum concentrations, as well as six nonsensitized sera with ATG added in vitro.
141           IgG antibodies of HDM-allergic and nonsensitized subjects were directed against peptide epi
142 ll, and cytokine responses in sensitized and nonsensitized subjects.
143 0; P = .0410) for Api g 7-sensitized versus -nonsensitized subjects.
144  response to Der f 1 allergen (sensitized vs nonsensitized) to inform a gene-environment study of dus
145                           Confocal images of nonsensitized tracheas showed slight fluorescence for P2
146                                    Efficient nonsensitized visible-light photolysis releases organoph
147 ransplanted into three groups of recipients: nonsensitized wild type, alloantigen-sensitized wild-typ
148 om mouse work is responsible for symptoms in nonsensitized workers.
149 ing hearts from A-Tg mice into sensitized or nonsensitized WT mice.
150 d DCs (BMDCs) were adoptively transferred to nonsensitized WT mice.

 
Page Top